• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tempus AI Inc.

    3/6/26 2:47:19 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tempus AI, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    02/28/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    ARK Investment Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    8,836,759.00
    6Shared Voting Power

    185,573.00
    7Sole Dispositive Power

    9,446,435.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,446,435.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.44 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Catherine D. Wood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,022,332.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,446,435.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,446,435.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.44 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tempus AI, Inc.
    (b)Address of issuer's principal executive offices:

    600 West Chicago Avenue, Suite 510, Chicago, IL 60654
    Item 2. 
    (a)Name of person filing:

    (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
    (b)Address or principal business office or, if none, residence:

    ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
    (c)Citizenship:

    (i) ARK: Delaware (ii) Catherine D. Wood: United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    88023B103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    ARK and Catherine D. Wood: 9,446,435
    (b)Percent of class:

    ARK and Catherine D. Wood: 5.44
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) ARK: 8,836,759 (ii) Catherine D. Wood: 0

     (ii) Shared power to vote or to direct the vote:

    (i) ARK: 185,573 (ii) Catherine D. Wood: 9,022,332

     (iii) Sole power to dispose or to direct the disposition of:

    (i) ARK: 9,446,435 (ii) Catherine D. Wood: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) ARK: 0 (ii) Catherine D. Wood: 9,446,435

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARK Investment Management LLC
     
    Signature:/s/ Kellen Carter
    Name/Title:Kellen Carter, Chief Compliance Officer
    Date:03/06/2026
     
    Catherine D. Wood
     
    Signature:/s/ Catherine D. Wood
    Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
    Date:03/06/2026
    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    2/19/2026$100.00Outperform
    Mizuho
    2/17/2026$59.00Outperform
    Robert W. Baird
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    More analyst ratings

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Epstein David R sold $12,672 worth of shares (250 units at $50.69), decreasing direct ownership by 0.96% to 25,801 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:27 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Rogers James William sold $578,576 worth of shares (11,414 units at $50.69), decreasing direct ownership by 8% to 127,248 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:25 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    New insider Schoenherr Thomas Edward claimed ownership of 94,967 shares (SEC Form 3)

    3 - Tempus AI, Inc. (0001717115) (Issuer)

    2/25/26 7:12:07 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck's oncology and potentially broader therapeutic portfolios. "This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients," said Ryan Fukushima, CEO, Data & Apps at Tempus. "We've spent years configuring our Lens Platform to seamlessly lever

    3/3/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_key=e25fc24c17&tp_special=8. A recording will be made available on the Events page of Tempus' Investor Relations website. About Tempus Tempus is a technology company advancing precision medicine through the practical applicati

    2/26/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Tempus AI Inc.

    SCHEDULE 13G - Tempus AI, Inc. (0001717115) (Subject)

    3/6/26 2:47:19 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    3/2/26 4:38:26 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form S-8 filed by Tempus AI Inc.

    S-8 - Tempus AI, Inc. (0001717115) (Filer)

    2/24/26 4:58:11 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Tempus AI with a new price target

    Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00

    2/19/26 7:52:33 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Robert W. Baird initiated coverage on Tempus AI with a new price target

    Robert W. Baird initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $59.00

    2/17/26 8:19:06 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Morgan Stanley resumed coverage on Tempus AI with a new price target

    Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

    12/2/25 8:35:17 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

    2/18/26 11:45:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology